A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetylsalicylic acid in healthy volunteers under fasting conditions.
Phase 1
Active, not recruiting
- Conditions
- increased blood clottingMedDRA version: 20.0Level: PTClassification code: 10002383Term: Angina pectoris Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2023-509841-12-00
- Lead Sponsor
- Cepha s.r.o.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method